Arcturus ARCT-810 Phase 2 interim: glutamine normalized, ureagenesis improved (p=0.026)

Arcturus Therapeutics Holdings Inc.

Combined Phase 2 data show glutamine significantly reduced (p=0.0055); levels normalized after 3 doses in US study.
15N-ureagenesis function (RUF) increased from 29.0% baseline to 43.7% at day 28 post-fifth dose (p=0.026).
Ammonia remained stable and within normal range in both studies; one hyperammonemia event on placebo.
ARCT-810 safe and well tolerated across Phase 1/2 with no serious infusion reactions on optimized 3-hour regimen.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.